Treating rectal cancer with radiation, chemo, and immunotherapy before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests giving radiation, chemotherapy, and immunotherapy before surgery for rectal cancer that has not spread far. The goal is to see if this combination shrinks the tumor more and improves outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and able to give written consent.
- You have rectal cancer that has not spread to other organs (no distant metastasis).
- The tumor must be reachable by surgery and imaging shows it is located within 12 cm of the anal verge.
- You are in good physical condition (able to care for yourself and be up and about).
- Your cancer must be the type called pMMR or MSS (a standard marker that affects how well certain treatments work).
- You have not had radiation therapy to the pelvis before, and you have not had chemo or immunotherapy in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests a new combination of short-course radiation, an immunotherapy drug called ivonescimab, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.